Shanghai – October 15, 2026 -- WuXi XDC (2268.HK) has won "Best CDMO" at the 2026 World ADC Awards for the fourth consecutive year and "Best CRO" for the second, making it the only contract research, development and manufacturing organization (CRDMO) to take both titles two years running.

Singapore – September 21, 2026 -- WuXi XDC Cayman Inc. (2268.HK) has secured GMP release for its Singapore manufacturing site at Tuas Biomedical Park, marking the bioconjugate CRDMO's first overseas facility just two and a half years after the site was announced in March 2024.

Shanghai – September 19, 2026 -- WuXi XDC Cayman Inc. (2268.HK) has out-licensed its proprietary WuXiTecan-2 payload-linker technology platform to Ona Therapeutics under an exclusive global agreement targeting a single antibody-drug conjugate (ADC) candidate.